1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/59466
Full metadata record
DC FieldValueLanguage
dc.creatorGustavo Fernandespt_BR
dc.creatorDaniel Girardipt_BR
dc.creatorJoão Paulo Bernardespt_BR
dc.creatorFelipe Paiva Fonsecapt_BR
dc.creatorEduardo Fregnanipt_BR
dc.date.accessioned2023-10-16T19:32:11Z-
dc.date.available2023-10-16T19:32:11Z-
dc.date.issued2018-09-12-
dc.citation.volume18pt_BR
dc.citation.issue1pt_BR
dc.citation.spage887pt_BR
dc.identifier.doihttps://doi.org/10.1186%2Fs12885-018-4802-ypt_BR
dc.identifier.issn14712407pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/59466-
dc.description.resumoBackground: Ameloblastoma is a slow-growing neoplasm of the jaw, for which the standard treatment is surgical removal of the lesion with high recurrence rates and elevated morbidity. Systemic therapy is not established in the literature. Case presentation: We present a case of a 29-year-old woman diagnosed with an ameloblastoma of the left mandible who had been subjected to several surgical procedures over twenty years due to multiple local recurrences. Molecular testing revealed a BRAF V600E mutation, and vemurafenib was started. She experienced complete resolution of symptoms related to the disease, and image scans evidenced continuous shrinkage of the neoplastic lesion after eleven months of therapy. Conclusion: This is the first report showing clinical benefit and radiological response with vemrafenib for recurrent ameloblastoma. Targeted therapy addressing BRAF V600E mutation has the potential to change clinical practice of this rare disease.pt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentFAO - DEPARTAMENTO DE CLÍNICApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofBMC Cancerpt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectopen acess Clinical benefit and radiological response with braf inhibitor in a patient with recurrent ameloblastoma harboring v600e mutation busca dia 09 09 2023 assunto ameloblastoma fao clinicapt_BR
dc.subject.otherAmeloblastomapt_BR
dc.subject.otherNeoplasmspt_BR
dc.subject.otherMandiblept_BR
dc.titleClinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutationpt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134697/pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.pdf967.33 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.